Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Evaluating Reflexology Impact on Breast Cancer RT-Related Anxiety, Pain

October 17, 2024
By Heather Zinkin, MD
Commentary
Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.

CancerNetwork® spoke with Heather Zinkin, MD, chief of radiation medicine at Huntington Hospital of the Northwell Health Cancer Institute, about how reflexology was utilized in patients with breast cancer undergoing radiation therapy and how the efficacy of the intervention was assessed. She discussed this methodology in the context of a study she presented at the 2024 American Society of Radiation Oncology (ASTRO) Annual Meeting.

Zinkin began by highlighting the inclusion of a holistic nurse for a full workday every week, which was funded by the Northwell Center for Wellness and Integrative Medicine. She further explained that patients were offered a complimentary 15-minute session with the nurse for up to 5 weeks in a converted exam room which served as a quiet, meditative space.

Zinkin further outlined the process, whereby patients chose which portion of the body they wanted to receive reflexology, which was supplemented with mindfulness. She then stated that the impact of reflexology sessions was assessed through anonymous pre- and post-intervention stress thermometer surveys, which measured patient-reported energy, anxiety, and pain.

The study assessed 560 patient encounters from April 2022 through December 2023 to evaluate the impact of reflexology on patient-reported levels of stress, pain, and energy. Findings from the study showed that stress and pain were reduced by 40.0% and 24.0%, respectively, and that energy increased by 33.3%. Additionally, improvement in patient well-being overall was reported to have increased by 33.3% (P < .0001).

Transcript:

We were fortunately able to obtain funding from Northwell Center for Wellness and Integrative Medicine for a holistic nurse from their practice to come to our office for a full workday every week. Then we were able to offer every [patient with] breast cancer who was under treatment––receiving radiation therapy––a complimentary 15-minute session with her for up to 5 weeks. We converted one of our exam rooms into a quiet, meditative space with dim lighting, flameless candles, and some soft music. Women were able to choose what part of the body they preferred, whether it be their hands, their feet, or their neck, and they were offered 15 minutes of reflexology, including some mindfulness. Each patient was asked anonymously to complete a stress thermometer survey prior to and after each session so that we could evaluate the response to each therapy. We looked at various metrics, including energy, anxiety, and pain.

Reference

Zinkin HD, Kostroff K, Dimisa D, et al. Reflexology as an integrative approach to improve stress, energy, and pain in women receiving radiotherapy for breast cancer. Int J Radiat Oncol. 2024;120(suppl 2):e423. doi:10.1016/j.ijrobp.2024.07.944

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Related Content

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.


A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.


Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Second-Line Tarlatamab Improves PFS, OS in Small Cell Lung Cancer

Chris Ryan
June 5th 2025
Article

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.


Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Tony Berberabe, MPH
June 4th 2025
Article

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Related Content

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.


A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.


Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Second-Line Tarlatamab Improves PFS, OS in Small Cell Lung Cancer

Chris Ryan
June 5th 2025
Article

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.


Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Tony Berberabe, MPH
June 4th 2025
Article

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.